ClinicalTrials.gg
WithdrawnNCT03291158Updated Sep 21, 2023

Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV

A Phase 1 interventional study of Minocycline in Normal Healthy Volunteers, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). Withdrawn at 1 site in Austria. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) (part of Novartis) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.

Read the detailed description

The purpose of this study is to evaluate the safety of Minocin IV and measure plasma, epithelial lining fluid, and alveolar macrophage drug levels after six doses of Minocin IV given 12 hours apart, administered as 1-hour infusions in healthy adult subjects.

02

Conditions studied

  • Normal Healthy Volunteers

Browse trials for

Keywords

  • Bacterial Infections
03

In context

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Lead sponsor

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) is the lead sponsor of 7 studies on the registry; none are open to participants now.

First submitted before Rempex Pharmaceuticals became part of Novartis.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A signed form, the ability to understand the study conduct and tasks that are required for study participation, and a willingness to cooperate with all tasks, tests, and examinations as required by the protocol, whether in the hospital or after discharge, for the duration of the study;
  2. Healthy adult male or female between 18 and 55 years of age (inclusive) at the time of Screening;
  3. (BMI) ≥ 18.5 and ≤ 30 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive) at Screening;
  4. Subject is in good health based on medical history and physical examination findings and has no safety laboratory abnormalities (hematology, blood chemistry, and urinalysis) or 12-lead results, as assessed by the Principal Investigator (PI);
  5. Vital signs (blood pressure [BP], pulse, and temperature) measured at Screening/baseline must be within the following ranges: systolic BP ≥90 to ≤150 mm Hg, diastolic BP ≥45 to ≤90 mm Hg; Heart Rate ≥ 45 to ≤90 bpm (taken after resting in a supine position for at least 5 minutes);
  6. Expectation that intravenous access will be sufficient to allow for ease of study drug infusion and for all protocol-required blood sampling to take place;
  7. Subject commits to remaining under observation of the study staff for the course of the study;
  8. Female subject is surgically sterile (bilateral tubal occlusion), , or if of , agrees to abstinence or to use a highly efficient method of (i.e., intrauterine device [IUD] or intrauterine hormone-releasing system [IUS] or vasectomized male partner, or hormonal contraceptives [estrogen and progestogen combined or progestogen only] with inhibition of ovulation; oral hormonal contraceptives must be supplemented with the use of condoms), between inclusion and for 7 days after the completion of the study;
  9. If male, agree to be sexually abstinent or agree to use an approved method of contraception (e.g., condom with spermicide) when engaging in sexual activity from study check-in through 7 days after completion of the study, and to not donate sperm during this same period of time.

Exclusion criteria

Exclusion Criteria:

  1. Has any condition, including findings in the medical history or in pre-study assessments that constitutes a risk or a for the participation in the study or completing the study;
  2. Any acute illness, including infection within 30 days prior to Day 1;
  3. Surgery within the past three months prior to Day 1 determined by the PI to be clinically relevant;
  4. Positive breath test for alcohol on Day 1 (pre-dose) and/or positive urine test for drugs of abuse at Screening/Day -1 visit;
  5. Has a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse is defined as regularly consuming >3 units/day (21 units per week for men) and >2 units/day (14 units/week) for women. A unit is defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), or a glass of wine (100 mL);
  6. Subject is a smoker and smokes >5 cigarettes per day (or equivalent);
  7. Use of non-tobacco/nicotine-containing products within 6 months prior to Day 1;
  8. Current diagnosis of or positive at Screening for and/or ;
  9. Blood or plasma donation within past 2 months;
  10. Females who are pregnant or nursing or who have a positive pregnancy test result at Screening;
  11. Presence of known raised intracranial pressure;
  12. Use of isotretinoin;
  13. History of significant or allergic reaction to tetracycline antibiotics;
  14. History of allergic or other serious adverse reactions to lidocaine;
  15. Clinically significant pulmonary or any other disease that prevents a subject from undergoing bronchoscopy with bronchopulmonary lavage;
  16. History of seizures (e.g., epilepsy), head injury, or meningitis requiring ongoing anti-seizure medications;
  17. Receipt of any medication or investigational device during the last 30 days prior to randomization;
  18. Vigorous exercise from 48 hours prior to Day -1 until the day of discharge from the study;
  19. Treatment with any prescription or over-the-counter drugs, within two weeks of day 1, with the exception of acetaminophen/paracetamol for minor headache. or other hormone replacement is also permitted as long as it has been taken at a stable dose for at least three months before the Screening visit and remains stable for the duration of the study;
  20. Unable or unwilling to comply with the protocol;
  21. An employee of the PI or study center with direct involvement in the proposed study or other studies under the direction of that PI or study center, or a family member of the employee or the PI
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Minocycline IV

    Open label Minocin IV

    Drug: Minocycline

Interventions

  • Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.

    Also known as: Minocin IV

06

What researchers measure

Primary outcomes

  1. Analyze plasma, ELF and Alveolar Macrophage concentrations of minocycline

    Determine plasma ELF and Alveolar Macrophage concentrations of minocycline when administered to healthy adult subjects.

    Time frame: 16 weeks

Secondary outcomes

  1. Safety and Tolerability

    To assess the safety and tolerability of Minocin IV when administered to healthy adult subjects by assessing adverse events, changes from baseline in physical examination findings, clinical safety laboratory test results, ECGs, and vital signs throughout the study.

    Time frame: 16 weeks

07

Study locations

1 site
  • Medical University of Vienna
    Vienna, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2018; primary completion for Dec 2018, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Sep 25, 2017
StartEst.
Apr 2018
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03291158
Collaborators
Universitätsklinikum Köln, Innovative Medicines Initiative
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Apr 2018 (estimated)
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Sep 21, 2023

Study contacts

Markus Zeitlinger, MD
principal investigator · University of Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minocycline

Start the discussion